Ranbaxy's 2010 profit surges but flat sales seen ahead
This article was originally published in Scrip
Ranbaxy Laboratories expects to report flat base sales in 2011, even as its profit after tax for the year ended 31 December 2010 surged to Rs14.97 billion ($327 million) from Rs2.96 billion in the previous year.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.